SCHEMBL4974653

SCHEMBL4974653

O=C(O)OC1(N2C(=O)CCC2=O)CCC(CN2C(=O)C=CC2=O)CC1

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 4/20 0.31
PTGS2 P35354 4/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22163860 0.83
SCHEMBL15969015 0.80 PSEN1 (0.31)
SCHEMBL342325 0.80 PSEN1 (0.31)
SCHEMBL2431617 0.76 MGLL (0.30)
SCHEMBL29111500 0.75 PSEN1 (0.32)
SCHEMBL2511023 0.75
SCHEMBL28366699 0.74
SCHEMBL10446959 0.73 PSEN1 (0.31)
SCHEMBL28921010 0.73 PSEN1 (0.31)
SCHEMBL28646512 0.72 MGLL (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689428-B2 Polypeptides, nucleic acids and uses thereof AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2020-06-23 US disclosed
US-20180265559-A1 POLYPEPTIDES, NUCLEIC ACIDS AND USES THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-09-20 US disclosed
US-9309314-B2 Polypeptides, nucleic acids and uses thereof AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) 2016-04-12 US disclosed
US-20160054300-A1 REFERENCE STANDARD FOR DIAGNOSTIC APPLICATIONS WINTHER LARS (DK) 2016-02-25 US disclosed
US-20150299311-A1 POLYPEPTIDES, NUCLEIC ACIDS AND USES THEREOF AGENCY SCIENCE TECH & RES (SG) 2015-10-22 US disclosed
US-20150153365-A1 POLYPEPTIDES, NUCLEIC ACIDS AND USES THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) 2015-06-04 US disclosed
EP-1642131-B1 STANDARD DAKO DENMARK AS (DK) 2008-10-29 EP disclosed
US-20070037138-A1 Standard for immunohistochemistry, immunocytochemistry and molecular cytogenetics DAKOCYTOMATION DENMARK A/S (DK) 2007-02-15 US disclosed
EP-1597578-B1 STANDARD FOR IMMUNOHISTOCHEMISTRY, IMMUNOCYTOCHEMISTRY AND MOLECULAR CYTOGENETICS. DAKO DENMARK AS (DK) 2006-12-20 EP disclosed
US-20060154234-A1 Standard WINTHER LARS 2006-07-13 US disclosed
EP-0438206-B1 6-Ring-containing macrocyclic tetraaza compounds, processes for their preparation, and pharmaceutical agents containing them SCHERING AG (DE) 1996-08-21 EP disclosed
EP-0516063-A1 Antibody-enzyme complex and enzyme immunoassay using it SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1992-12-02 EP disclosed
EP-0441468-A2 Gas-containing microparticles composed of polyaldehydes as contrast agents SCHERING AKTIENGESELLSCHAFT (DE) 1991-08-14 EP disclosed
EP-0438206-A1 6-Ring-containing macrocyclic tetraaza compounds, processes for their preparation, and pharmaceutical agents containing them SCHERING AKTIENGESELLSCHAFT (DE) 1991-07-24 EP disclosed
EP-0430863-A2 Complexe builders bonded to sterwise prepared polymers, their complexes and conjugates, process for their preparation and pharmaceutical agents containing the same SCHERING AKTIENGESELLSCHAFT (DE) 1991-06-05 EP disclosed
EP-0149168-B1 IMMUNOASSAY DAIICHI PURE CHEMICALS CO. LTD. (JP) 1991-04-24 EP disclosed
EP-0331616-A2 Polymer-bonded complexe builders, their complexes, process for their preparation and pharmaceutical agents containing the same SCHERING AKTIENGESELLSCHAFT (DE) 1989-09-06 EP disclosed
EP-0277088-A2 Polymer complexes, process for their preparation and pharmaceutical compounds containing them SCHERING AKTIENGESELLSCHAFT (DE) 1988-08-03 EP disclosed
US-4690907-A Capillary tube immunoassay DAIICHI PURE CHEMICALS CO., LTD. (JP) 1987-09-01 US disclosed
EP-0149168-A1 Immunoassay DAIICHI PURE CHEMICALS CO. LTD. (JP) 1985-07-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180265559-A1 POLYPEPTIDES, NUCLEIC ACIDS AND USES THEREOF CXXC4, CXXC5, ZFX PTGS1 4744/4885PTGS2 4825/4885
US-20150153365-A1 POLYPEPTIDES, NUCLEIC ACIDS AND USES THEREOF CXXC4, CXXC5, ZFX PTGS1 4744/4885PTGS2 4825/4885
US-20150299311-A1 POLYPEPTIDES, NUCLEIC ACIDS AND USES THEREOF CXXC4, CXXC5, ZFX PTGS1 4744/4885PTGS2 4825/4885
US-10689428-B2 Polypeptides, nucleic acids and uses thereof CXXC4, CXXC5, ZFX PTGS1 4744/4885PTGS2 4825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.